Latanoprost
FDA-approved product (solution/drops, ophthalmic), marketed as Iyuzeh, Latanoprost, Xalatan and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
- Hypertension
- Ocular hypertension
- Open-angle glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Prostaglandin analogues
- FDA pharmacologic class
- Prostaglandin Analog FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Latanoprost with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
NCT04737928 · start 2018-04-02
Registered record
- Registry ID
- NCT04737928
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- Latanoprost; tafluprost
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2018-04-02
- Completion
- 2019-01-22
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Primary Open AngleInterventionLatanoprost; tafluprostPhaseNot applicableRegistry statusCompletedEfficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
NCT03331770 · start 2017-01-06
Registered record
- Registry ID
- NCT03331770
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- Latanoprost Ophthalmic Product
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-01-06
- Completion
- 2017-10-06
- Enrolment
- 103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Open-angle GlaucomaInterventionLatanoprost Ophthalmic ProductPhasePhase 4Registry statusCompletedA Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
NCT02981446 · start 2017-01
Registered record
- Registry ID
- NCT02981446
- Conditions
- Open Angle Glaucoma or Ocular Hypertension
- Interventions
- DE-117; Latanoprost ophthalmic solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-01
- Completion
- 2019-01
- Enrolment
- 370
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen Angle Glaucoma or Ocular HypertensionInterventionDE-117; Latanoprost ophthalmic solutionPhasePhase 3Registry statusCompletedA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
NCT02622334 · start 2015-12-29
Registered record
- Registry ID
- NCT02622334
- Conditions
- Glaucoma
- Interventions
- Latanoprost; Placebo; RO5093151
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-12-29
- Completion
- 2016-07-28
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionLatanoprost; Placebo; RO5093151PhasePhase 1Registry statusCompletedComparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
NCT02167035 · start 2014-08
Registered record
- Registry ID
- NCT02167035
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- Combigan Two Times Daily (BID); Simbrinza Three Times Daily (TID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-08
- Completion
- 2018-03
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionCombigan Two Times Daily (BID); Simbrinza Three Times Daily (TID)PhasePhase 4Registry statusCompletedPharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
NCT02108288 · start 2014-04
Registered record
- Registry ID
- NCT02108288
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- OPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution; Latanoprost ophthalmic solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2014-08
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma; Ocular HypertensionInterventionOPC-1085EL ophthalmic solution; Carteolol long-acting ophthalmic solution; Latanoprost ophthalmic solutionPhasePhase 1Registry statusCompletedEfficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension
NCT02047630 · start 2014-01
Registered record
- Registry ID
- NCT02047630
- Conditions
- Primary Open Angle Glaucoma; Ocular Hypertension
- Interventions
- Generic latanoprost; Brand-name latanoprost
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2014-01
- Completion
- 2014-12-04
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Open Angle Glaucoma; Ocular HypertensionInterventionGeneric latanoprost; Brand-name latanoprostPhasePhase 4Registry statusTerminatedStudy to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
NCT01896180 · start 2013-07
Registered record
- Registry ID
- NCT01896180
- Conditions
- Primary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular Pressure
- Interventions
- ALZ-1101; Latanoprost
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2014-01
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular PressureInterventionALZ-1101; LatanoprostPhasePhase 2Registry statusCompletedSafety and Efficacy of Liposomal Latanoprost in Ocular Hypertension
NCT01987323 · start 2013-01
Registered record
- Registry ID
- NCT01987323
- Conditions
- Ocular Hypertension
- Interventions
- Subconjunctival injection of liposomal latanoprost
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2013-06
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular HypertensionInterventionSubconjunctival injection of liposomal latanoprostPhasePhase 1 / Phase 2Registry statusCompletedEfficacy of Changing to TRAVATAN® From Prior Therapy
NCT01493427 · start 2011-12
Registered record
- Registry ID
- NCT01493427
- Conditions
- Open-Angle Glaucoma; Ocular Hypertension
- Interventions
- Travoprost 0.004%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2013-02
- Enrolment
- 202
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOpen-Angle Glaucoma; Ocular HypertensionInterventionTravoprost 0.004%PhasePhase 4Registry statusCompletedIntraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy
NCT01426464 · start 2011-09
Registered record
- Registry ID
- NCT01426464
- Conditions
- Glaucoma
- Interventions
- 0.005% Latanoprost dosed once.
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2011-09
- Completion
- 2011-12
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaIntervention0.005% Latanoprost dosed once.PhasePhase 2Registry statusUnknownLatanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
NCT01162603 · start 2011-03
Registered record
- Registry ID
- NCT01162603
- Conditions
- Primary Open Angle Glaucoma; Ocular Hypertension
- Interventions
- Goldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPS
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-03
- Completion
- 2012-04
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary Open Angle Glaucoma; Ocular HypertensionInterventionGoldmann and Perkins applanation tonometry; TAFLUPROST 0.0015% EYEDROPS; LATANOPROST 0.005% EYEDROPSPhasePhase 4Registry statusCompletedA Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
NCT01229982 · start 2010-10
Registered record
- Registry ID
- NCT01229982
- Conditions
- Ocular Hypertension; Open Angle Glaucoma
- Interventions
- Latanoprost-PPDS
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2011-08
- Enrolment
- 121
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular Hypertension; Open Angle GlaucomaInterventionLatanoprost-PPDSPhasePhase 2Registry statusCompletedThe Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
NCT01369771 · start 2010-08
Registered record
- Registry ID
- NCT01369771
- Conditions
- Ocular Hypertension; Open-Angle Glaucoma
- Interventions
- Tafluprost 0.0015%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-08
- Completion
- 2012-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular Hypertension; Open-Angle GlaucomaInterventionTafluprost 0.0015%PhasePhase 4Registry statusCompleted24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
NCT01448837 · start 2010-04
Registered record
- Registry ID
- NCT01448837
- Conditions
- Glaucoma
- Interventions
- Bimatoprost/Timolol, 24-hour intraocular pressure monitoring; Latanoprost, 24-hour intraocular pressure monitoring
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2011-03
- Enrolment
- 37
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionBimatoprost/Timolol, 24-hour intraocular pressure monitoring; Latanoprost, 24-hour intraocular pressure monitoringPhasePhase 4Registry statusCompleted